| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2227 |
| Trial ID | NCT04150913 |
| Disease | Non-Hodgkin's Lymphoma | Neurotoxicity Syndromes |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | YesCAR-Ta|Axicabtagene Ciloleucel|axi-cel |
| Co-treatment | anakinra |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity |
| Year | 2019 |
| Country | United States |
| Company sponsor | Massachusetts General Hospital |
| Other ID(s) | 19-348 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||